- Trials with a EudraCT protocol (194)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
194 result(s) found for: Recall test.
Displaying page 6 of 10.
EudraCT Number: 2010-022897-14 | Sponsor Protocol Number: PreMENAC-2011-01 | Start Date*: 2011-05-02 |
Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology | ||
Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II) | ||
Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) GB (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000812-27 | Sponsor Protocol Number: 055 | Start Date*: 2019-05-09 |
Sponsor Name:IMEA | ||
Full Title: Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FAST | ||
Medical condition: HIV positive age > 18 years - newly diagnosed HIV-infected individual evidenced by any tests - antiretroviral-treatment naive - negative urine pregnancy test - willing to sign an informed written... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005241-38 | Sponsor Protocol Number: LX6171.1-201-AAMI | Start Date*: 2007-11-12 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) ... | |||||||||||||
Medical condition: Age-Associated Memory Impairment (AAMI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002581-51 | Sponsor Protocol Number: AK002-006 | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:Allakos Inc. | |||||||||||||
Full Title: An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria | |||||||||||||
Medical condition: Patients with different types of chronic urticaria resistant to standard dose antihistamines | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004854-25 | Sponsor Protocol Number: SPON803-10 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: TRON: A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosis. | |||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002213-19 | Sponsor Protocol Number: ELICE-BD-O1 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:University of British Columbia | |||||||||||||
Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa... | |||||||||||||
Medical condition: Euthymic Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005817-61 | Sponsor Protocol Number: iVAC-CLL01 | Start Date*: 2016-07-28 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: iVAC-CLL01: Patient-individualized peptide vaccination after first line therapy of CLL | |||||||||||||
Medical condition: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) after first line therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001721-13 | Sponsor Protocol Number: TAK-013/EC-302 | Start Date*: 2005-01-24 | |||||||||||
Sponsor Name:Takeda Europe R&D Center Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001720-21 | Sponsor Protocol Number: TAK-013/EC301 | Start Date*: 2004-12-24 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010227-62 | Sponsor Protocol Number: GE-067-005 | Start Date*: 2009-09-09 | |||||||||||
Sponsor Name:GE Healthcare Ltd and its Affiliates | |||||||||||||
Full Title: A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (F18) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzhei... | |||||||||||||
Medical condition: GE-067-005 will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer for predicting the conversion from amnestic Mild Cognitive Impairment to probable Alzheimer’s disease. Uptake... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004369-29 | Sponsor Protocol Number: 206854 | Start Date*: 2018-04-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGYTM ELLIPTATM) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003284-19 | Sponsor Protocol Number: CTU/2013/073 | Start Date*: 2017-01-24 |
Sponsor Name:University College London | ||
Full Title: DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease. | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001839-23 | Sponsor Protocol Number: 14137A | Start Date*: 2012-05-14 |
Sponsor Name:H. Lundbeck A/S | ||
Full Title: Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted fro... | ||
Medical condition: Cognitive dysfunction Major depressive disorder (MDD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005327-16 | Sponsor Protocol Number: | Start Date*: 2014-07-15 | |||||||||||
Sponsor Name:The University of Edinburgh
[...]
1. The University of Edinburgh
2. NHS Lothian |
|||||||||||||
Full Title: A Randomized Open Label Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function after Colorectal Surgery | |||||||||||||
Medical condition: Post-operative pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002751-10 | Sponsor Protocol Number: ELDCOG | Start Date*: 2015-10-05 | ||||||||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | ||||||||||||||||||
Full Title: DIFFERENCE BETWEEN NEUROCOGNITIVE IMPACT WITH CHEMOTHERAPY AND RADIATION THERAPY HYPOFRACTIONATED TEMOZOLOMIDE AS SINGLE AGENT IN ELDERLY PATIENTS (= 70 YEARS) WITH NEWLY DIAGNOSED GLIOBLASTOMA: A ... | ||||||||||||||||||
Medical condition: NEWLY DIANGOSED GLIOBLASTOMA ELDERLY PATIENTS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002490-26 | Sponsor Protocol Number: ACT17208 | Start Date*: 2021-10-08 | |||||||||||
Sponsor Name:Sanofi aventis recherche et developpement | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group, 12 week Proof-of-Concept (PoC) study to assess the efficacy, safety, and tolerability of rilzabrutinib in participants with moderate-... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000403-15 | Sponsor Protocol Number: 01-06-TL-375-081 | Start Date*: 2007-07-25 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Polysomnography plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults with Chronic Insomnia | |||||||||||||
Medical condition: insomnia characterised by difficulty with sleep onset | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) DE (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004692-36 | Sponsor Protocol Number: VAR/01/011 | Start Date*: 2011-11-30 | ||||||||||||||||
Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE | ||||||||||||||||||
Full Title: COMBIVAR. Randomized double-blind trial of two parallel groups design to evaluate the efficacy of smoking cessation with combined (varenicline plus nicotine patches) versus monotherapy (varenicline) | ||||||||||||||||||
Medical condition: NICOTINE DEPENDENCE. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020475-23 | Sponsor Protocol Number: B0041007 | Start Date*: 2010-10-05 | |||||||||||
Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO-WAY CROSS-OVER, MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY... | |||||||||||||
Medical condition: Chronic pain in patients with Osteo-arthritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002787-32 | Sponsor Protocol Number: RG_19-172 | Start Date*: 2020-11-16 |
Sponsor Name:University of Birmingham | ||
Full Title: Antidepressant for the prevention of DEPression following first episode Psychosis trial | ||
Medical condition: Patients with First Episode Psychosis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
